These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 28677106)
1. Expression and prognostic value of JAM-A in gliomas. Rosager AM; Sørensen MD; Dahlrot RH; Boldt HB; Hansen S; Lathia JD; Kristensen BW J Neurooncol; 2017 Oct; 135(1):107-117. PubMed ID: 28677106 [TBL] [Abstract][Full Text] [Related]
2. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas. Dahlrot RH Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629 [TBL] [Abstract][Full Text] [Related]
3. Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients. Zhang M; Song T; Yang L; Chen R; Wu L; Yang Z; Fang J J Exp Clin Cancer Res; 2008 Dec; 27(1):85. PubMed ID: 19108713 [TBL] [Abstract][Full Text] [Related]
4. In vitro neurosphere formation correlates with poor survival in glioma. C Jayakrishnan P; H Venkat E; M Ramachandran G; K Kesavapisharady K; N Nair S; Bharathan B; Radhakrishnan N; Gopala S IUBMB Life; 2019 Feb; 71(2):244-253. PubMed ID: 30393962 [TBL] [Abstract][Full Text] [Related]
5. Clinical value of CD133 and nestin in patients with glioma: a population-based study. Dahlrot RH; Hansen S; Jensen SS; Schrøder HD; Hjelmborg J; Kristensen BW Int J Clin Exp Pathol; 2014; 7(7):3739-51. PubMed ID: 25120750 [TBL] [Abstract][Full Text] [Related]
6. Malignant clinical features of anaplastic gliomas without IDH mutation. Shibahara I; Sonoda Y; Shoji T; Kanamori M; Saito R; Inoue T; Kawaguchi T; Yamashita Y; Watanabe T; Kumabe T; Watanabe M; Suzuki H; Tominaga T Neuro Oncol; 2015 Jan; 17(1):136-44. PubMed ID: 24958096 [TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of stem cell marker CD133 determined by promoter methylation but not by immunohistochemical expression in malignant gliomas. Wu X; Wu F; Xu D; Zhang T J Neurooncol; 2016 Apr; 127(2):221-32. PubMed ID: 26757925 [TBL] [Abstract][Full Text] [Related]
8. What is the clinical value of cancer stem cell markers in gliomas? Dahlrot RH; Hermansen SK; Hansen S; Kristensen BW Int J Clin Exp Pathol; 2013; 6(3):334-48. PubMed ID: 23412423 [TBL] [Abstract][Full Text] [Related]
9. Expression and Prognostic Value of Oct-4 in Astrocytic Brain Tumors. Krogh Petersen J; Jensen P; Dahl Sørensen M; Winther Kristensen B PLoS One; 2016; 11(12):e0169129. PubMed ID: 28030635 [TBL] [Abstract][Full Text] [Related]
10. Expansion of CD133-positive glioma cells in recurrent de novo glioblastomas after radiotherapy and chemotherapy. Tamura K; Aoyagi M; Ando N; Ogishima T; Wakimoto H; Yamamoto M; Ohno K J Neurosurg; 2013 Nov; 119(5):1145-55. PubMed ID: 23991844 [TBL] [Abstract][Full Text] [Related]
11. Neural stem cell markers, nestin and musashi proteins, in the progression of human glioma: correlation of nestin with prognosis of patient survival. Strojnik T; Røsland GV; Sakariassen PO; Kavalar R; Lah T Surg Neurol; 2007 Aug; 68(2):133-43; discussion 143-4. PubMed ID: 17537489 [TBL] [Abstract][Full Text] [Related]
12. Differential expression of p42.3 in low- and high-grade gliomas. Wan W; Xu X; Jia G; Li W; Wang J; Ren T; Wu Z; Zhang J; Zhang L; Lu Y World J Surg Oncol; 2014 Jun; 12():185. PubMed ID: 24927751 [TBL] [Abstract][Full Text] [Related]
13. The prognostic significance of androgen receptor expression in gliomas. Zhang C; Zhao N; Khan R; Hung MY; Zhang C; Wang S; Wang TJC; Lin C Sci Rep; 2024 Sep; 14(1):22122. PubMed ID: 39333688 [TBL] [Abstract][Full Text] [Related]
14. Tumour-associated microglia/macrophages predict poor prognosis in high-grade gliomas and correlate with an aggressive tumour subtype. Sørensen MD; Dahlrot RH; Boldt HB; Hansen S; Kristensen BW Neuropathol Appl Neurobiol; 2018 Feb; 44(2):185-206. PubMed ID: 28767130 [TBL] [Abstract][Full Text] [Related]
15. MIF Receptor CD74 is Restricted to Microglia/Macrophages, Associated with a M1-Polarized Immune Milieu and Prolonged Patient Survival in Gliomas. Zeiner PS; Preusse C; Blank AE; Zachskorn C; Baumgarten P; Caspary L; Braczynski AK; Weissenberger J; Bratzke H; Reiß S; Pennartz S; Winkelmann R; Senft C; Plate KH; Wischhusen J; Stenzel W; Harter PN; Mittelbronn M Brain Pathol; 2015 Jul; 25(4):491-504. PubMed ID: 25175718 [TBL] [Abstract][Full Text] [Related]
16. High expression of the stem cell marker nestin is an adverse prognostic factor in WHO grade II-III astrocytomas and oligoastrocytomas. Hatanpaa KJ; Hu T; Vemireddy V; Foong C; Raisanen JM; Oliver D; Hiemenz MC; Burns DK; White CL; Whitworth LA; Mickey B; Stegner M; Habib AA; Fink K; Maher EA; Bachoo RM J Neurooncol; 2014 Mar; 117(1):183-189. PubMed ID: 24519516 [TBL] [Abstract][Full Text] [Related]
17. Do relevant markers of cancer stem cells CD133 and Nestin indicate a poor prognosis in glioma patients? A systematic review and meta-analysis. Wu B; Sun C; Feng F; Ge M; Xia L J Exp Clin Cancer Res; 2015 May; 34(1):44. PubMed ID: 25967234 [TBL] [Abstract][Full Text] [Related]
18. Glial progenitor-like phenotype in low-grade glioma and enhanced CD133-expression and neuronal lineage differentiation potential in high-grade glioma. Rebetz J; Tian D; Persson A; Widegren B; Salford LG; Englund E; Gisselsson D; Fan X PLoS One; 2008 Apr; 3(4):e1936. PubMed ID: 18398462 [TBL] [Abstract][Full Text] [Related]
19. Periostin is a new potential prognostic biomarker for glioma. Tian B; Zhang Y; Zhang J Tumour Biol; 2014 Jun; 35(6):5877-83. PubMed ID: 24719188 [TBL] [Abstract][Full Text] [Related]
20. The overexpression of epithelial cell adhesion molecule (EpCAM) in glioma. Chen X; Ma WY; Xu SC; Liang Y; Fu YB; Pang B; Xin T; Fan HT; Zhang R; Luo JG; Kang WQ; Wang M; Pang Q J Neurooncol; 2014 Aug; 119(1):39-47. PubMed ID: 24906438 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]